|
Bristol-Myers Squibb Company (BMY) DCF Valoración
US | Healthcare | Drug Manufacturers - General | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Bristol-Myers Squibb Company (BMY) Bundle
¡Obtenga información sobre su análisis de valoración de Bristol-Myers Squibb Company (BMY) utilizando nuestra sofisticada calculadora DCF! Completamente equipado con datos reales (BMY), esta plantilla de Excel le permite ajustar los pronósticos y supuestos para determinar con precisión el valor intrínseco de Bristol-Myers Squibb Company.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26,145.0 | 42,518.0 | 46,385.0 | 46,159.0 | 45,006.0 | 48,831.1 | 52,981.3 | 57,484.2 | 62,369.8 | 67,670.7 |
| Revenue Growth, % | 0 | 62.62 | 9.09 | -0.48723 | -2.5 | 8.5 | 8.5 | 8.5 | 8.5 | 8.5 |
| EBITDA | 7,440.0 | 5,035.0 | 20,191.0 | 19,232.0 | 19,366.0 | 16,458.3 | 17,857.1 | 19,374.7 | 21,021.4 | 22,808.0 |
| EBITDA, % | 28.46 | 11.84 | 43.53 | 41.66 | 43.03 | 33.7 | 33.7 | 33.7 | 33.7 | 33.7 |
| Depreciation | 1,809.0 | 10,486.0 | 10,759.0 | 10,287.0 | 9,811.0 | 9,655.1 | 10,475.7 | 11,366.0 | 12,332.0 | 13,380.1 |
| Depreciation, % | 6.92 | 24.66 | 23.19 | 22.29 | 21.8 | 19.77 | 19.77 | 19.77 | 19.77 | 19.77 |
| EBIT | 5,631.0 | -5,451.0 | 9,432.0 | 8,945.0 | 9,555.0 | 6,803.2 | 7,381.4 | 8,008.8 | 8,689.4 | 9,427.9 |
| EBIT, % | 21.54 | -12.82 | 20.33 | 19.38 | 21.23 | 13.93 | 13.93 | 13.93 | 13.93 | 13.93 |
| Total Cash | 12,346.0 | 14,546.0 | 13,979.0 | 9,123.0 | 12,280.0 | 15,491.1 | 16,807.7 | 18,236.2 | 19,786.1 | 21,467.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7,685.0 | 8,501.0 | 12,516.0 | 13,937.0 | 15,264.0 | 13,719.5 | 14,885.6 | 16,150.7 | 17,523.4 | 19,012.7 |
| Account Receivables, % | 29.39 | 19.99 | 26.98 | 30.19 | 33.92 | 28.1 | 28.1 | 28.1 | 28.1 | 28.1 |
| Inventories | 4,293.0 | 2,074.0 | 2,095.0 | 2,339.0 | 2,662.0 | 3,593.6 | 3,899.0 | 4,230.4 | 4,590.0 | 4,980.1 |
| Inventories, % | 16.42 | 4.88 | 4.52 | 5.07 | 5.91 | 7.36 | 7.36 | 7.36 | 7.36 | 7.36 |
| Accounts Payable | 2,445.0 | 2,713.0 | 2,949.0 | 3,040.0 | 3,259.0 | 3,507.8 | 3,805.9 | 4,129.4 | 4,480.3 | 4,861.1 |
| Accounts Payable, % | 9.35 | 6.38 | 6.36 | 6.59 | 7.24 | 7.18 | 7.18 | 7.18 | 7.18 | 7.18 |
| Capital Expenditure | -836.0 | -753.0 | -973.0 | -1,118.0 | -1,209.0 | -1,189.0 | -1,290.1 | -1,399.7 | -1,518.7 | -1,647.7 |
| Capital Expenditure, % | -3.2 | -1.77 | -2.1 | -2.42 | -2.69 | -2.43 | -2.43 | -2.43 | -2.43 | -2.43 |
| Tax Rate, % | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 |
| EBITAT | 3,892.5 | -7,136.0 | 8,146.1 | 7,337.6 | 9,085.2 | 5,886.2 | 6,386.5 | 6,929.3 | 7,518.2 | 8,157.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4,667.5 | 4,268.0 | 14,132.1 | 14,932.6 | 16,256.2 | 15,213.9 | 14,398.8 | 15,622.5 | 16,950.3 | 18,390.9 |
| WACC, % | 5.64 | 6 | 5.84 | 5.79 | 5.94 | 5.84 | 5.84 | 5.84 | 5.84 | 5.84 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 67,754.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 18,759 | |||||||||
| Terminal Value | 488,209 | |||||||||
| Present Terminal Value | 367,543 | |||||||||
| Enterprise Value | 435,298 | |||||||||
| Net Debt | 30,000 | |||||||||
| Equity Value | 405,298 | |||||||||
| Diluted Shares Outstanding, MM | 2,078 | |||||||||
| Equity Value Per Share | 195.04 |
What You Will Get
- Pre-Filled Financial Model: Bristol-Myers Squibb’s actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
- Instant Calculations: Automatic updates ensure you see results as you make changes.
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.
Key Features
- Accurate Financial Data: Gain access to reliable pre-loaded historical figures and future forecasts for Bristol-Myers Squibb Company (BMY).
- Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to tailor your analysis.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
- User-Friendly Dashboard: Utilize clear charts and summaries to effectively visualize your valuation insights.
- Designed for All Skill Levels: A straightforward, intuitive layout catering to investors, CFOs, and consultants alike.
How It Works
- Download: Obtain the pre-prepared Excel file featuring Bristol-Myers Squibb’s financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and analyze results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Bristol-Myers Squibb (BMY)?
- Designed for Industry Experts: A sophisticated tool tailored for analysts, financial officers, and consultants.
- Accurate Financial Data: Historical and projected financials for Bristol-Myers Squibb preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly Interface: Step-by-step guidance ensures a smooth experience.
Who Should Use This Product?
- Investors: Evaluate Bristol-Myers Squibb's valuation before making stock trades.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess forecasts.
- Startup Founders: Discover how leading pharmaceutical companies like Bristol-Myers Squibb are appraised.
- Consultants: Provide comprehensive valuation analyses for your clients.
- Students and Educators: Utilize real-time data to practice and teach valuation strategies.
What the Template Contains
- Historical Data: Includes Bristol-Myers Squibb’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Bristol-Myers Squibb’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Bristol-Myers Squibb’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.